Rockefeller Capital Management’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.9K Buy
1,491
+842
+130% +$16.1K ﹤0.01% 3842
2026
Q2
$11.8K Hold
649
– – ﹤0.01% 3944
2026
Q1
$9.22K Buy
+649
New +$8.34K ﹤0.01% 4021
2022
Q3
– Sell
-221
Closed -$2K – 3919
2022
Q2
$2K Buy
+221
New +$2.51K ﹤0.01% 3756

Other funds holding CGEM

Rockefeller Capital Management's CGEM Position: Q3 2026 in Review

Rockefeller Capital Management increased its Cullinan Therapeutics (CGEM) stake by 130% in Q3 2026, buying an estimated $16.1K and bringing the position to 1,491 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3842.

Rockefeller Capital Management first reported a position in CGEM in Q2 2022 and has held it in 4 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Rockefeller Capital Management held 1,491 shares of Cullinan Therapeutics worth $22.9K as of Q3 2026.
  • Rockefeller Capital Management bought 842 Cullinan Therapeutics shares in Q3 2026, an estimated $16.1K.
  • Cullinan Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3842 holding.
  • Rockefeller Capital Management first reported a position in Cullinan Therapeutics in Q2 2022 and has held it in 4 quarters since.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.